Roland Wilhelm Kolbeck - 02 Feb 2026 Form 4 Insider Report for Aclaris Therapeutics, Inc. (ACRS)

Reporting relationship: Chief Scientific Officer
Issuer ticker: ACRS
Reported as of: 02 Feb 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 06 Feb 2026, 18:06:23 UTC
Prior SEC filing: 05 Aug 2025
Next SEC filing: 04 Aug 2026
Source filing: View source filing
Reporting owner signature: /s/ Matthew Rothman, Attorney-in-Fact

Key filing fact

Roland Wilhelm Kolbeck filed Form 4 for Aclaris Therapeutics, Inc. (ACRS) on 06 Feb 2026.

Key facts

This page summarizes Roland Wilhelm Kolbeck's Form 4 filing for Aclaris Therapeutics, Inc. (ACRS).
2 reported transactions and 2 derivative rows are listed below.
Accepted by SEC: 06 Feb 2026, 18:06.

Change

Previous filing in this sequence was filed on 05 Aug 2025.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0002076327 Primary reporting owner

Kolbeck Roland Wilhelm

Relationship: Chief Scientific Officer
Address: C/O ACLARIS THERAPEUTICS, INC., 701 LEE ROAD, SUITE 103, WAYNE
Signature: /s/ Matthew Rothman, Attorney-in-Fact
Signature date: 06 Feb 2026

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

ACRS transaction Derivative

Restricted Stock Units

Award

Transaction value: $0
Shares: +95,700
Change %
Price: $0.000000
Shares after: 95,700
Date: 02 Feb 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 95,700
Exercise price
Footnotes: F1, F2

ACRS transaction Derivative

Employee Stock Option (Right to Buy)

Award

Transaction value: $0
Shares: +334,900
Change %
Price: $0.000000
Shares after: 334,900
Date: 02 Feb 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 334,900
Exercise price: $3.61
Footnotes: F3

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 3 footnotes

Footnote F1

Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer.

Footnote F2

The shares underlying these restricted stock units vest in four equal installments on the first, second, third and fourth anniversaries of February 2, 2026, subject to the Continuous Service (as defined in the Plan) of the Reporting Person as of each such date.

Footnote F3

Exercisable with respect to 25% of the shares subject to the option vesting in four equal installments on the first, second, third and fourth anniversaries of February 2, 2026, subject to the Continuous Service (as defined in the Plan) of the Reporting Person as of each such date.